Automated multiplex LC-MS/MS assay for quantifying serum apolipoproteins A-I, B, C-I, C-II, C-III, and E with qualitative apolipoprotein E phenotyping

Clinical Chemistry

Volumn 62, Issue 1, 2016, Pages 188-197

  Van Den Broek, Irene ^a   Romijn, Fred P H T M ^a   Nouta, Jan ^a   Van Der Laarse, Arnoud ^a   Drijfhout, Jan W ^a   Smit, Nico P M ^a   Van Der Burgt, Yuri E M ^a   Cobbaert, Christa M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; PLASMA PROTEIN; TRYPSIN; APOLIPOPROTEIN;

ANALYZER; ARTICLE; AUTOANALYSIS; CALIBRATION; DYSLIPIDEMIA; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERTRIGLYCERIDEMIA; IMMUNOASSAY; IMMUNOTURBIDIMETRIC ASSAY; LIPID ANALYSIS; LIQUID CHROMATOGRAPHY; MEASUREMENT ACCURACY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEOMICS; QUALITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TURBIDIMETRY; AUTOMATION; BLOOD; DYSLIPIDEMIAS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHOTOMETRY;

APOLIPOPROTEINS; AUTOMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEPHELOMETRY AND TURBIDIMETRY; PHENOTYPE; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84954534319     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.246702     Document Type: Article

References (37)

1. Yusuf S, Hawken S, Ounpuu S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart Study): case-control study. Lancet 2004;364:937-52.
2. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006;259:493-519.
3. Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011;48:498-515.
4. Chan DC, Chen MM, Ooi EM, Watts GF. An abc of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 2008;62:799-809.
5. Kei AA, Filippatos TD, Tsimihodimos V, Elisaf MS. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012;61:906-21.
6. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3. Arterioscler Thromb Vasc Biol 1999;19:472-84.
7. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol 2001;12:297-304.
8. Marais AD, Solomon GA, Blom DJ. Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. Crit Rev Clin Lab Sci 2014;51:46-62.
9. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol 2010;21:337-45.
10. Langlois MR, Descamps OS, van der Laarse A, Weykamp C, Baum H, Pulkki K, et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM collaborative project group. Atherosclerosis 2014;233:83-90.
11. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
12. Chen Y, Snyder MR, Zhu Y, Tostrud LJ, Benson LM, Katzmann JA, Bergen HR 3rd. Simultaneous phenotyping and quantification of alpha-1-antitrypsin by liquid chromatography-tandem mass spectrometry. Clin Chem 2011;57:1161-8.
13. Hoofnagle AN. Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: Assessing the platform. Clin Chem 2010;56:161-4.
14. Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin Chem 2012;58:777-81.
15. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple-reactionmonitoring mass spectrometry. Clin Chem 2010;56:1804-13.
16. Ceglarek U, Dittrich J, Becker S, Baumann F, Kortz L, Thiery J. Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC-MS/MS. Proteomics Clin Appl 2013;7:794-801.
17. Rezeli M, Vegvari A, Fehniger TE, Laurell T, Marko-Varga G. Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels. J Clin Bioinforma 2011;1:7.
18. Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007;21:2585-93.
19. Smit NP, Romijn FP, van den Broek I, Drijfhout JW, Haex M, van der Laarse A, et al. Metrological traceability in mass spectrometry-based targeted protein quantitation: a proof-of-principle study for serum apolipoproteins A-I and B100. J Proteomics 2014;109C:143-61.
20. Rezeli M, Vegvari A, Donnarumma F, Gidlof O, Smith JG, Erlinge D, Marko-Varga G. Development of an MRM assay panel with application to biobank samples from patients with myocardial infarction. J Proteomics 2013;87:16-25.
21. Lassman ME, McLaughlin TM, Somers EP, Stefanni AC, Chen Z, Murphy BA, et al. A rapid method for crossspecies quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2012;26:101-8.
22. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009;8:1860-77.
23. Barr JR, Maggio VL, Patterson DG Jr, Cooper GR, Henderson LO, Turner WE, et al. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996;42:1676-82.
24. Simon R, Girod M, Fonbonne C, Salvador A, Clement Y, Lanteri P, et al. Total apoE and apoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n=669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics 2012;11:1389-403.
25. Wildsmith KR, Han B, Bateman RJ. Method for the simultaneous quantitation of apolipoprotein E isoforms using tandem mass spectrometry. Anal Biochem 2009;395:116-8.
26. Martinez-Morillo E, Nielsen HM, Batruch I, Drabovich AP, Begcevic I, Lopez MF, et al. Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein E isoforms. J Proteome Res 2014;13:1077-87.
27. Wang M, Chen J, Turko IV. 15N-labeled full-length apolipoprotein E4 as an internal standard for mass spectrometry quantification of apolipoprotein E isoforms. Anal Chem 2012;84:8340-4.
28. Carr SA, Abbatiello SE, Ackermann BL, Borchers C, Domon B, Deutsch EW, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014;13:907-17.
29. Smit NP, van den Broek I, Romijn FP, Haex M, Deelder AM, van der Burgt YE, et al. Quality requirements for quantitative clinical chemistry proteomics. Translational Proteomics 2014;2:1-13.
30. van den Broek I, Romijn FP, Smit NP, van der Laarse A, Drijfhout JW, van der Burgt YE, Cobbaert CM. Quantifying protein measurands by peptide measurements: where do errors arise? J Proteome Res 2015;14:928-42.
31. van den Broek I, Smit NP, Romijn FP, van der Laarse A, Deelder AM, van der Burgt YE, Cobbaert CM. Evaluation of interspecimen trypsin digestion efficiency prior to multiple reaction monitoring-based absolute protein quantification with native protein calibrators. J Proteome Res 2013;12:5760-74.
32. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81.
33. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40:586-92.
34. CLSI. User verification of performance for precision and trueness; approved guideline-second edition. Wayne (PA): CLSI; 2005. CLSI doc. EP15-A2.
35. CLSI. Measurement procedure comparison and bias estimation using patient samples; approved guideline-third edition. Wayne (PA): CLSI; 2013. CLSI doc. EP09-A3.
36. CLSI. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. Wayne (PA): CLSI; 2003. CLSI doc. EP06-A.
37. Trenchevska O, Schaab MR, Nelson RW, Nedelkov D. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods 2015;81:86-92.